{"id":1312,"date":"2024-09-11T18:54:11","date_gmt":"2024-09-11T18:54:11","guid":{"rendered":"https:\/\/newsletters.aans.org\/tumor\/?page_id=1312"},"modified":"2024-09-26T14:13:48","modified_gmt":"2024-09-26T14:13:48","slug":"clinical-trials-in-neuro-oncology","status":"publish","type":"page","link":"https:\/\/newsletters.aans.org\/tumor\/fall-2024\/clinical-trials-in-neuro-oncology\/","title":{"rendered":"Clinical Trials in Neuro-Oncology"},"content":{"rendered":"

Important Dates:<\/u><\/strong><\/p>\n

EORTC Brain Cancer Group: Glasgow, UK; October 16, 2024<\/p>\n

Alliance Fall Meeting (Hybrid): Chicago, IL; October 30-November 1, 2024<\/p>\n

NRG Winter Meeting: Phoenix, AZ; January 16-18, 2025<\/p>\n

Alliance Spring Meeting (Hybrid): Chicago, IL; April 30-May 3, 2025<\/p>\n

NRG Summer Meeting: Washington, DC; July 24-26, 2025<\/p>\n

In the spring report, we highlighted the Alliance trial \u201cA071401, Phase II Trial of SMO\/ AKT\/ NF2\/CDK Inhibitors in Progressive Meningiomas with SMO\/ AKT\/ NF2\/CDK Pathway Mutations.\u201d<\/p>\n

In this report, we highlight the NRG trial BN003 \u201cPhase III trial of observation versus irradiation for a gross totally resected grade II meningioma.\u201d\u00a0 The aim of the study is to compare the clinical outcomes (progression free survival) of adjuvant RT versus observation for patients with newly diagnosed grade 2 meningiomas who undergo gross total resection. Patients are randomized to receive RT versus observation. Secondary outcomes include overall survival, neurocognitive function and patient reported outcomes. Accrual is ongoing. Target enrollment is 163 patients. PI is Leland Rogers, MD.<\/p>\n

For additional information on joining these meetings or workgroups, please visit the following links or reach out to the following contacts:<\/p>\n

NRG:<\/p>\n

Webpage: https:\/\/www.nrgoncology.org\/Meetings<\/a><\/p>\n

Contact: meeting-reg@nrgoncology.org<\/a><\/p>\n

 <\/p>\n

Alliance:<\/p>\n

Webpage: https:\/\/www.allianceforclinicaltrialsinoncology.org\/main\/public\/standard.xhtml?path=%2FPublic%2FMeetings<\/a><\/p>\n

Contact: Meetings@AllianceNCTN.org<\/a><\/p>\n

 <\/p>\n

EORTC:<\/p>\n

Webpage: https:\/\/www.eortc.org\/event\/eortc-brain-tumour-group-autumn-meeting-3\/<\/a><\/p>\n

Contact: events@eortc.org<\/a><\/p>\n

 <\/p>\n

QOD-Tumor Registry<\/strong><\/p>\n

The current price point is a three-year contract at $5,000\/year plus funding of a 0.5 FTE for data entry. Patient accrual and startup of interested neurosurgical groups has increased steadily since the Tumor QOD opened.<\/p>\n

A total of 13 centers are actively enrolling patients with an additional seven centers in contract. The registry includes outcomes from 129 neurosurgeons and more than 4,621 patients, of which 2,870 patients have three-month follow-up including quality of life metrics. The registry has newly formed a Committee for Outcomes Research (CORe), which will initiate new retrospective and prospective studies among active centers.<\/p>\n

Those interested in more information regarding participating in the QOD-Tumor Registry should contact Brad Elder at brad.elder@osumc.edu<\/a>, Raj Mukherjee at drraj@jhmi.edu<\/a> or Michele Anderson at manderson@neuropoint.org<\/a><\/p>\n

 <\/p>\n

 <\/p>\n","protected":false},"excerpt":{"rendered":"

Important Dates: EORTC Brain Cancer Group: Glasgow, UK; October 16, 2024 Alliance Fall Meeting (Hybrid): Chicago, IL; October 30-November 1, 2024 NRG Winter Meeting: Phoenix, AZ; January 16-18, 2025 Alliance Spring Meeting (Hybrid): Chicago, IL; April 30-May 3, 2025 NRG Summer Meeting: Washington, DC; July 24-26, 2025 In the spring report, we highlighted the Alliance […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":1295,"menu_order":6,"comment_status":"closed","ping_status":"closed","template":"NewsletterTOC.php","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-1312","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\nClinical Trials in Neuro-Oncology - Tumor News<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/newsletters.aans.org\/tumor\/fall-2024\/clinical-trials-in-neuro-oncology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clinical Trials in Neuro-Oncology - Tumor News\" \/>\n<meta property=\"og:description\" content=\"Important Dates: EORTC Brain Cancer Group: Glasgow, UK; October 16, 2024 Alliance Fall Meeting (Hybrid): Chicago, IL; October 30-November 1, 2024 NRG Winter Meeting: Phoenix, AZ; January 16-18, 2025 Alliance Spring Meeting (Hybrid): Chicago, IL; April 30-May 3, 2025 NRG Summer Meeting: Washington, DC; July 24-26, 2025 In the spring report, we highlighted the Alliance […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/newsletters.aans.org\/tumor\/fall-2024\/clinical-trials-in-neuro-oncology\/\" \/>\n<meta property=\"og:site_name\" content=\"Tumor News\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-26T14:13:48+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2024\\\/clinical-trials-in-neuro-oncology\\\/\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2024\\\/clinical-trials-in-neuro-oncology\\\/\",\"name\":\"Clinical Trials in Neuro-Oncology - Tumor News\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#website\"},\"datePublished\":\"2024-09-11T18:54:11+00:00\",\"dateModified\":\"2024-09-26T14:13:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2024\\\/clinical-trials-in-neuro-oncology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2024\\\/clinical-trials-in-neuro-oncology\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2024\\\/clinical-trials-in-neuro-oncology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Fall 2024\",\"item\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/fall-2024\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Clinical Trials in Neuro-Oncology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#website\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/\",\"name\":\"Tumor News\",\"description\":\"Just another AANS Newsletter Sites site\",\"publisher\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#organization\",\"name\":\"Tumor News\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/newsletters.aans.org\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2024\\\/11\\\/JST.2024.logo_.png\",\"contentUrl\":\"https:\\\/\\\/newsletters.aans.org\\\/wp-content\\\/uploads\\\/sites\\\/5\\\/2024\\\/11\\\/JST.2024.logo_.png\",\"width\":2336,\"height\":2294,\"caption\":\"Tumor News\"},\"image\":{\"@id\":\"https:\\\/\\\/newsletters.aans.org\\\/tumor\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clinical Trials in Neuro-Oncology - Tumor News","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/newsletters.aans.org\/tumor\/fall-2024\/clinical-trials-in-neuro-oncology\/","og_locale":"en_US","og_type":"article","og_title":"Clinical Trials in Neuro-Oncology - Tumor News","og_description":"Important Dates: EORTC Brain Cancer Group: Glasgow, UK; October 16, 2024 Alliance Fall Meeting (Hybrid): Chicago, IL; October 30-November 1, 2024 NRG Winter Meeting: Phoenix, AZ; January 16-18, 2025 Alliance Spring Meeting (Hybrid): Chicago, IL; April 30-May 3, 2025 NRG Summer Meeting: Washington, DC; July 24-26, 2025 In the spring report, we highlighted the Alliance […]","og_url":"https:\/\/newsletters.aans.org\/tumor\/fall-2024\/clinical-trials-in-neuro-oncology\/","og_site_name":"Tumor News","article_modified_time":"2024-09-26T14:13:48+00:00","twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/newsletters.aans.org\/tumor\/fall-2024\/clinical-trials-in-neuro-oncology\/","url":"https:\/\/newsletters.aans.org\/tumor\/fall-2024\/clinical-trials-in-neuro-oncology\/","name":"Clinical Trials in Neuro-Oncology - Tumor News","isPartOf":{"@id":"https:\/\/newsletters.aans.org\/tumor\/#website"},"datePublished":"2024-09-11T18:54:11+00:00","dateModified":"2024-09-26T14:13:48+00:00","breadcrumb":{"@id":"https:\/\/newsletters.aans.org\/tumor\/fall-2024\/clinical-trials-in-neuro-oncology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/newsletters.aans.org\/tumor\/fall-2024\/clinical-trials-in-neuro-oncology\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/newsletters.aans.org\/tumor\/fall-2024\/clinical-trials-in-neuro-oncology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/newsletters.aans.org\/tumor\/"},{"@type":"ListItem","position":2,"name":"Fall 2024","item":"https:\/\/newsletters.aans.org\/tumor\/fall-2024\/"},{"@type":"ListItem","position":3,"name":"Clinical Trials in Neuro-Oncology"}]},{"@type":"WebSite","@id":"https:\/\/newsletters.aans.org\/tumor\/#website","url":"https:\/\/newsletters.aans.org\/tumor\/","name":"Tumor News","description":"Just another AANS Newsletter Sites site","publisher":{"@id":"https:\/\/newsletters.aans.org\/tumor\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/newsletters.aans.org\/tumor\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/newsletters.aans.org\/tumor\/#organization","name":"Tumor News","url":"https:\/\/newsletters.aans.org\/tumor\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/newsletters.aans.org\/tumor\/#\/schema\/logo\/image\/","url":"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2024\/11\/JST.2024.logo_.png","contentUrl":"https:\/\/newsletters.aans.org\/wp-content\/uploads\/sites\/5\/2024\/11\/JST.2024.logo_.png","width":2336,"height":2294,"caption":"Tumor News"},"image":{"@id":"https:\/\/newsletters.aans.org\/tumor\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/1312","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/comments?post=1312"}],"version-history":[{"count":1,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/1312\/revisions"}],"predecessor-version":[{"id":1313,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/1312\/revisions\/1313"}],"up":[{"embeddable":true,"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/pages\/1295"}],"wp:attachment":[{"href":"https:\/\/newsletters.aans.org\/tumor\/wp-json\/wp\/v2\/media?parent=1312"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}